Market Overview

UPDATE: Jefferies Raises PT on BioMarin Pharmaceutical as BMN-701 Moves Forward

Related BMRN
UPDATE: UBS Securities Reiterates On BioMarin Pharmaceutical On Path To Long-Term Upside
FDA Grants BioMarin Orphan Drug Designation for NAGLU Fusion Protein, BMN 250, for the Treatment of MPS IIIB

In a report published Wednesday, Jefferies analyst Eun K. Yang reiterated a Buy rating on BioMarin Pharmaceutical (NASDAQ: BMRN), and raised the price target from $65.00 to $70.00.

In the report, Yang noted, “On decent Ph1/2 data, BMRN makes a go decision for BMN-701 for Pompe disease - positive. However, to us, it's uncertain if BMN-701 is indeed superior to Lumizyme; planned Ph2/3 single-arm, switching study (subject to FDA discussion) makes it difficult to compare efficacy. While not as exciting, even at comparable efficacy to Lumizyme, we continue to view BMN-701 has reasonable commercial potential (Lumizyme with ~$610M in FY12 sales).”

BioMarin Pharmaceutical closed on Tuesday at $60.76.

Latest Ratings for BMRN

DateFirmActionFromTo
Dec 2014JP MorganMaintainsOverweight
Dec 2014UBSMaintainsBuy
Nov 2014JefferiesMaintainsBuy

View More Analyst Ratings for BMRN
View the Latest Analyst Ratings

Posted-In: JefferiesAnalyst Color Price Target Analyst Ratings

 

Related Articles (BMRN)

Around the Web, We're Loving...

Get Benzinga's Newsletters